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A B S T R A C T
Purpose: To further elucidate possible immune-modulatory effects of valproate (VPA) or levetiracetam
(LEV), we investigated their inﬂuence on apoptosis and cytotoxic function of CD8+ T lymphocytes in
humans.
Methods: In 15 healthy subjects (9 female (60%), 35.7  12.1 years), apoptosis and cytotoxic function of
CD8+ T lymphocytes were measured using ﬂow cytometry following in vitro exposure to LEV (5 mg/L and
50 mg/L) and VPA (10 mg/L and 100 mg/L). Apoptosis rates were determined after incubation with LEV or
VPA for 1 h or 24 h. Cytotoxic function was assessed following 2 h stimulation with mixed virus peptides,
using perforin release, CD107a/b expression and proliferation. The presence of synaptic vesicle protein 2A
(SV2A) was investigated in human CD8+ T lymphocytes by ﬂow cytometry analysis, Western blot and real
time polymerase chain reaction (rtPCR).
Results: High concentration of LEV decreased perforin release of CD8+ T lymphocytes (LEV 50 mg/L vs.
CEF only: 21.4% (interquartile range (IQR) 16.5–35.9%) vs. 16.6% (IQR 12–24.9%), p = 0.002). LEV had no
inﬂuence on apoptosis and proliferation (p > 0.05). VPA (100 mg/L) slowed apoptosis of CD8+ T
lymphocytes after 24 h (VPA 100 mg/L vs. control: 7.3% (IQR 5.4–9.5%) vs. 11.3% (IQR 8.2–15.1%),
p < 0.001), but had no effects on perforin release (p > 0.05). SV2A protein was detected in CD8+ T
lymphocytes.
Conclusion: LEV decreased degranulation of CD8+ T lymphocytes which may contribute to the increased
incidence of upper respiratory tract infections in LEV treated patients. Inhibition of SV2A may be
responsible for this effect.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Levetiracetam (LEV) is a new generation antiepileptic drug
whose efﬁcacy and tolerability in epilepsy treatment is well
recognized.1,2 Synaptic vesicle protein 2A (SV2A), an intracellular
protein, is the binding site of levetiracetam in the brain.3 Several
clinical trials reported a clear anticonvulsant effect of LEV but also
an increased incidence of pharyngitis and rhinitis in LEV-treated
patients.4–9 The reason for this latter ﬁnding remains unknown. It
was reported that white blood cell and neutrophil counts were in
the normal range in levetiracetam-treated patients who developed
infections8 but were signiﬁcantly decreased during treatment
compared to the pretreatement status.9 Similarly, we found
interictally no clear effect of LEV on B lymphocytes as well asvier Ltd. All rights reserved.
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patients.10
The primary role of CD8+ T lymphocytes is to protect against
viral infections by lysing infected cells via degranulation-
dependent perforin release which can be measured by increased
expression of CD107a and CD107b on the cell surface11 and
secretion of soluble factors, such as interferon-g (IFN-g) and
tumor necrosis factor-a (TNFa).12–15 Treatment with valproate
(VPA) was not found to be associated with a higher infection
rate.16 However, VPA is a potent histone deacetylase (HDAC)
inhibitor17–19 and histone modiﬁcation plays a role in the
regulation of the effector functions of memory CD8+ T cells.20
Moreover, VPA can induce apoptosis in various leukemia cells
in vivo and in vitro.17–19 VPA also inﬂuenced postictal blood
levels of TNFa and interleukin (IL)-1b as well as CD4+ T cell
counts.21,22
In this study, we investigated the inﬂuence of LEV and VPA on
proliferation, apoptosis, CD107 mobilization and perforin release
of CD8+ T lymphocytes in vitro in order to better understand their
pharmacological effects and adverse events.
2. Materials and methods
2.1. Study population
Fifteen healthy adult volunteers recruited from the staff of the
Department of Neurology, University of Marburg (9 female (60%),
age: 35.7  12.1 years; range: 18–60 years) were included in the
study. None of the volunteers took any medication. Immediately after
venous blood drawing (10 mL), the experiments were started. The
study was approved by the local ethics committee.
2.2. Antibodies, reagents and peptides
We used the following antibodies, reagents and peptides: CD3-
APC, CD8-PerCP, perforin-PE, IgG2b-PE isotype control, CD107a/
b-FITC, Perm/Wash BufferTM, Cytoﬁx/CytopermTM solution, BD
GolgiStopTM (all BD Bioscience), recombinant human interleukin-
2 (rhIL-2) (ProSpec), SV2A-FITC (ByOrbit), IgG-FITC isotype
control (antibodies-online GmbH), Polyclonal antibody to
SV2A-Aff-Puriﬁed (Acris Antibodies GmbH), IgG-HRP (Santa Cruz
Biotechnology) Annexin V-FITC apoptosis detection kit (Mountain
View), carboxyl ﬂuorescein succinimidyl ester (CFSE) (Invitro-
gen), pooled human AB serum (3H Biomedical AB), trypan blue
solution (0.4%) (GIBCO), RPMI 1640 and 1% penicillin–streptomy-
cin (Sigma) and CTL-CEF-Class I peptide pool ‘‘Plus’’ (Cell
Technolgy Ltd.).
2.3. Anticonvulsant drugs
Levetiracetam (Keppra1, UCB Pharma S.A., Brussels, Belgium)
and sodium valproate (Ergenyl1 vial, Sanoﬁ Aventis, Frankfurt,
Germany) were dissolved in sterile physiological saline to produce
fresh solutions as required. When treating cells, the drugs were
further diluted in the culture medium to the ﬁnal concentrations of
5 mg/L or 50 mg/L for LEV (serum reference range in adults for drug
fasting levels: 12–46 mg/L) and 10 mg/L or 100 mg/L for VPA
(serum reference range in adults for drug fasting levels: 50–
100 mg/L), respectively.23
2.4. Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
with Ficoll–Biocoll Separating Solution by density gradient
centrifugation (1500 rpm, 20 8C, 30 min, without brake) of
heparinized blood obtained by venipuncture of the healthyvolunteers. Viability of PBMCs obtained was always >95%, as
determined by 0.4% trypan blue staining. After double washing in
cold PBS, PBMCs were cultured with RPMI 1640 supplemented
with 10% heat-inactivated pooled human AB serum and 1%
penicillin–streptomycin.
2.5. Activation of CD8+ T lymphocytes
In the functional assays, CD8+ T lymphocytes were activated
with CTL-CEF-Class I peptide pool ‘‘Plus’’, which contains 32
peptides, each corresponding to a deﬁned HLA class I restricted T-
cell epitope from cytomegalovirus, Epstein–Barr virus and
inﬂuenza virus. Most humans have been previously exposed to
one or more of these pathogens, respectively. One hundred
microliter PBMCs (2–3  106 cells/mL) were incubated with
64 mg/mL of CEF peptide (100 mL) at 37 8C in a humidiﬁed, 5%
CO2 incubator for 2 h. Costimulatory antibodies (BD FastImmu-
neTM CD28/CD49d costimulatory reagent) were added according to
the manufacturer’s protocol. A negative control (only anti-CD28/
CD49d) was included in every experiment.
2.6. Perforin release
Perforin release was measured as previously described.24 After
activation of CD8+ T lymphocytes for 2 h either in the presence or
absence of anticonvulsant drugs, cells were ﬁrst stained with CD3-
APC and CD8-PerCP for 30 min and were then resuspended in BD
Cytoﬁx/Cytoperm solution for 20 min at 4 8C. After washing and
centrifugation (1200 rpm, 20 8C, 4 min), cells were labeled with
perforin-PE in Perm/Wash buffer solution. IgG2b-PE isotype
control was used for negative control. Perforin expression was
measured by ﬂow cytometry. The baseline of perforin expression
was measured in unstimulated cells immediately after isolation. A
reduction in degranulation was indicated by a higher percentage of
perforin+ cells remaining after stimulation.
2.7. CD107 mobilization
CD8+ T lymphocyte degranulation can also be measured by
increased expression of surface CD107a and CD107b.11,25 CD107
mobilization was measured as previously described.30 Brieﬂy,
CD107a/b-FITC and monensin (BD GolgiStop, used according to
manufacturer’s instructions) were added before activation of CD8+
T lymphocytes in the presence or absence of anticonvulsant drugs.
After incubation for 2 h, cells were washed and stained with CD3-
APC- and CD8-PerCP-antibodies as described above followed by
characterization of cells in the ﬂow cytometer. The baseline of
CD107a/b expression was measured in unstimulated cells imme-
diately after isolation.
2.8. Analysis of CD8+ T lymphocyte proliferation by CFSE labeling
PBMCs were labeled with 0.4 mM CFSE at 37 8C for 10 min in the
dark. Free CFSE was quenched with ice-cold culture medium for
5 min. Following two washes, the labeled cells were resuspended
in the culture medium. Costimulatory antibodies (CD28/CD49d)
and 100 mL of CEF peptides were added into 100 mL of CFSE-
labeled PBMCs (2–3  106 cells/mL) in the presence or absence of
anticonvulsant drugs. Recombinant human IL-2 (40 IU/mL) was
added at the time of peptide stimulation. The negative control
consisted of cultures of CFSE-labeled, unstimulated cells. After
incubation in a 5% CO2 incubator at 37 8C for 5 days, cells were
washed with culture medium and cell surfaces were stained with
CD3-APC and CD8-PerCP. Cells were analyzed by ﬂow cytometry.
The deﬁnition for low CFSE cells was deﬁned according to the
distribution of CSFE in unstimulated cells.
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Fresh isolated PBMCs were ﬁrst stained with CD3-APC and CD8-
PerCP and incubated for 30 min. Then, stained PBMCs were
resuspended in BD Cytoﬁx/Cytoperm solution for 20 min at 4 8C.
After washing and centrifugation (1200 rpm, 20 8C, 4 min), cells
were labeled with SV2A-FITC in Perm/Wash buffer solution. IgG-
FITC isotype control was used as negative control. Expression of
SV2A was measured by ﬂow cytometry in 3 samples because the
study focus lay on possible alterations of function induced by
levetiracetam and not on modes of action.
To conﬁrm ﬂow cytometry results, Western blot analysis and
rtPCR were additionally performed. First, we used FICOLL as
described above for isolation of PBMCs and further CD8+ T
lymphocytes for separation into CD8+ cell populations with
MicroBeads (human CD8 MikroBeads, Miltenyi Biotec, Bergisch
Gladbach, Germany) using magnetic activated cell sorting (MACS,
Miltenyi Biotec) according to the manufacturer’s instructions. This
led to a count of 3 million CD8+ cells. Protein was extracted with
mammalian protein extraction reagent (10 mL, MPER, Pierce)
according to manufacturer’s instructions. Additionally protease
inhibitor complex (Protease Inhibitor Cocktail Tablets, Boehringer
Ingelheim, Germany) was used for prevention of protein degrada-
tion.
For Western blot analysis, protein was separated on 10% SDS-
PAGE gels (Rotiphorese 10 SDS PAGE, Rotiphorese Gel 30, TRIS
HCl, Roth, Karlsruhe, Germany) by electrophoresis. Gels were
transferred to nitrocellulose membranes (Invitrogen, Germany)
and processed as described for protein assays. Brieﬂy, Roti-Block
blocking buffer (Roth, Karlsruhe, Germany) was used for blocking
the blots, incubation with the SV2A antibody (1:1000) overnight at
4 8C followed. After washing with PBS/0.05% Tween 20, the blots
were incubated for 2 h with HRP-conjugated secondary antibody
(1:1000, rabbit anti goat IgG-HRP) at room temperature.
Actin-HRP antibody (Goat anti actin HRP) served as loading
control.
Total RNA was isolated from PBMCs with RNeasy Mini Kit
(Quiagen Inc.) according to manufacturer’s instructions. Total RNA
(2 mg) was reverse transcribed with 200 U/mL of Superscipt II
Rnase H-Reverese Transcription (Invitrogen), using Oligo(dT)12–18
primers (Pd(T)12–18: #277858-25UT) according to the manufac-
turer’s instructions.
SV2a mRNA levels were determined by using the Applied
Biosystems 7900 HT Thermal Cycler. The ampliﬁcation protocol
consisted of ﬁrst step at 50 8C for 2 min, a denaturation step at
95 8C for 10 min, followed by 50 cycles with a 95 8C denaturation
step for 15 s and 60 8C annealing for 60 s. The following primers
were used for speciﬁc ampliﬁcation.
SV2a: Hs00372069_m1 (Applied Biosystems) and b-Actin:
TaqMan b-actin Detection Reagent (Applied Biosystems).
PCR products were analyzed by melting curve analysis. A
negative control (no template) was measured in each of the PCR
runs. The cDNA copy number of SV2a was calculated in relation to
the ampliﬁcation product amount of internal standard.
2.10. Apoptosis evaluation
Fresh PBMCs were seeded at 2–3  105 cells/well in 96-well
plates and LEV (5 mg/L or 50 mg/L) or VPA (10 mg/L or 100 mg/L)
was added, respectively. PBMCs without addition of anticonvul-
sants served as controls. After incubation for 1 h or 24 h at 37 8C in
a humidiﬁed, 5% CO2–air incubator, plates were centrifuged
(1200 rpm, 20 8C, 4 min) and supernatants were aspirated. The
cells were stained with CD3-APC and CD8-PerCP for 30 min in the
dark on ice. Annexin V Apoptosis Detection Kit was used to detectapoptosis. Brieﬂy, after washing with culture medium and
centrifugation (1200 rpm, 20 8C, 4 min), the cells were resus-
pended in 200 mL of Annexin V binding buffer and incubated with
2 mL of Annexin V-FITC and 2 mL of PI for 10 min in the dark at
room temperature. Then, Annexin-binding was measured on a
four-color ﬂow cytometer (FACSCalibur1, CellQuest1 software,
Becton Dickinson).
2.11. Statistical analysis
Intra-individual group comparisons were performed with
nonparametric Wilcoxon matched-pairs test because Gaussian
distribution could not assumed. The data are presented as median
values and interquartile ranges (IQR). Because of multiple testing
and the explorative nature of the study, the signiﬁcance level was
set to p < 0.01.
3. Results
3.1. Perforin release
Perforin release, CD107a/b expression and proliferation were
signiﬁcantly increased in the CEF-peptide stimulated cells as
compared to controls after incubation for 2 h, respectively (control
vs. CEF: remaining perforin: 40.2% (IQR 31.9–45.6%) vs. 16.6% (IQR
12–24.9%), p < 0.001; CD107a/b: 0.7% (IQR 0.3–1%) vs. 10.5% (IQR
8.4–13.9%), p < 0.001; low CFSE: 1.8% (IQR 1.4–2.7%) vs. 7% (IQR
4.3–9.7%), p < 0.001).
Perforin release was decreased in high concentration of LEV
(LEV 50 mg/L vs. CEF only: 21.4% (IQR 16.5–35.9%) vs. 16.6% (IQR
12–24.9%), p = 0.002) and showed a trend toward decreased
release in the low-concentration group (LEV 5 mg/L vs. CEF only:
23% (IQR 11.5–36.3%) vs. 16.6% (IQR 12–24.9%), p = 0.048) without
changes after addition of VPA (VPA 10 mg/L vs. CEF only: 18.9%
(IQR 8.7–33%) vs. 16.6% (IQR 12–24.9%), p = 0.33; VPA 100 mg/L vs.
CEF only: 17.3% (IQR 8.2–27.6%) vs. 16.6% (IQR 12–24.9%), p = 0.93)
(Fig. 1).
3.2. CD107a/b expression
After 2 h of stimulation, both high and low concentrations of
LEV decreased CD107a/b expression on CD8+ T lymphocytes
compared with the CEF-peptide stimulated group without LEV
(LEV 50 mg/L vs. CEF only: 5.5% (IQR 2.7–7.2%) vs. 10.5% (IQR 8.4–
13.9%), p < 0.001; LEV 5 mg/L vs. CEF only: 6.6% (IQR 4.8–8.3%) vs.
10.5% (IQR 8.4–13.9%), p < 0.001). VPA did not reveal any effect on
CD107a/b expression (VPA 100 mg/L vs. CEF only: 9.9% (IQR 6.7–
14%) vs. 10.5% (IQR 8.4–13.9%), p = 0.64; VPA 10 mg/L vs. CEF only:
10.1% (IQR 6.8–14.2%) vs. 10.5% (IQR 8.4–13.9%), p = 0.15) (Fig. 2).
3.3. Proliferation of CD8+ T lymphocytes
LEV and VPA did not inﬂuence proliferation of CD8+ T
lymphocytes induced by CEF-peptide stimulation (LEV 50 mg/L
vs. CEF only: 6.2% (IQR 4.4–8.7%) vs. 7% (IQR 4.3–9.7%), p = 0.85;
LEV 5 mg/L vs. CEF only: 5.9% (IQR 4.2–8.7%) vs. 7% (IQR 4.3–9.7%),
p = 0.43; VPA 100 mg/L vs. CEF only: 5.9% (IQR 3.8–9.4%) vs. 7% (IQR
4.3–9.7%), p = 0.78; VPA 10 mg/L vs. CEF only: 5.7% (IQR 4.3–9%) vs.
7% (IQR 4.3–9.7%), p = 0.81).
3.4. Expression of SV2A in human CD8+ T lymphocytes
SV2A could be detected in human CD8+ T lymphocytes by both
ﬂow cytometry and Western blot analysis. The rtPCR could verify
that mRNA for SV2A exists in PBMCs.
Fig. 2. CD107 expression on CD8+ T lymphocytes after 2 h of CEF-peptide
stimulation dependent on low and high concentrations of LEV or VPA. Data are
presented as median and interquartile range (IQR). CEF = CTL-CEF-Class I peptide
pool, LEV = levetiracetam, VPA = valproate, *p < 0.01.
G. Li et al. / Seizure 22 (2013) 462–466 4653.5. Apoptosis
Spontaneous apoptosis was observed in cells untreated with
LEV or VPA after incubation for 1 h and 24 h. In the high-
concentration VPA group, the percentage of apoptotic CD8+ T
lymphocytes was signiﬁcantly lower than that in the control group
after 24 h of incubation (VPA 100 mg/L vs. control: 7.3% (IQR 5.4–
9.5%) vs. 11.3% (IQR 8.2–15.1%), p < 0.001). None of the other
treatment groups showed signiﬁcant changes (VPA 10 mg/L vs.
control: 13.3% (IQR 7.6–14.9%) vs. 11.3% (IQR 8.2–15.1%), p = 0.42;
LEV 5 mg/L vs. control: 10.8% (IQR 9.3–13.1%) vs. 11.3% (IQR 8.2–
15.1%), p = 0.85; LEV 50 mg/L vs. control: 12.5% (IQR 9.3–14.4%) vs.
11.3% (IQR 8.2–15.1%), p = 0.17) (Fig. 3). After 1 h, there was no
signiﬁcant decrease in apoptosis of CD8+ T lymphocytes in any of
the groups (VPA 10 mg/L vs. control: 8.1% (IQR 5.4–11%) vs. 7.4%
(IQR 5.6–10.8%), p = 0.09; VPA 100 mg/L vs. control: 8.5% (IQR 5.8–
10.4%) vs. 7.4% (IQR 5.6–10.8%), p = 0.04; LEV 5 mg/L vs. control:
7.6% (IQR 6.6–10.3%) vs. 7.4% (IQR 5.6–10.8%), p = 0.17; LEV 50 mg/
L vs. control: 7.9% (IQR 6.2–10.9%) vs. 7.4% (IQR 5.6–10.8%),
p = 0.11).
4. Discussion
The main ﬁnding of this study was that LEV had an attenuating
effect on degranulation of CD8+ T lymphocytes as indicated by
reduced perforin release and decreased CD107a/b mobilization
after CEF-peptide stimulation in vitro. SV2A was found to exist in
human CD8+ T lymphocytes. Therefore, it can be hypothesized that
the inhibiting effect of LEV on the function of CD8+ T cells is
mediated by interaction of LEV with SV2A protein. LEV did not
appear to inﬂuence apoptosis or proliferation of CD8+ T lympho-
cytes. In contrast, high concentrations of VPA prevented sponta-
neous apoptosis of CD8+ T lymphocytes in vitro but did not have
any effects on proliferation or perforin release.
In clinical studies, LEV treatment increased the incidence of
pharyngitis and rhinitis which was associated with a slight but
signiﬁcant drop in white blood cell counts.9 Similarly, a study on
interictal alterations of leukocytes and cytokines in the blood of
patients with active epilepsy found a trend toward decreased
counts of CD8+ T lymphocytes.10
While this study did not conﬁrm a signiﬁcant effect of LEV on
apoptosis of CD8+ T lymphocytes in vitro, the results suggest that
LEV compromised the function of CD8+ T lymphocytes.Fig. 1. Perforin release of CD8+ T lymphocytes dependent on low and high
concentrations of LEV or VPA after 2 h of CEF-peptide stimulation. A reduction in
degranulation was indicated by a higher percentage of perforin+ cells remaining
after stimulation. Data are presented as median and interquartile range (IQR).
CEF = CTL-CEF-Class I peptide pool, LEV = levetiracetam, VPA = valproate, *p < 0.01.Cytotoxicity of CD8+ T lymphocytes is mainly mediated by
release of pre-formed cytolytic granules which contain perforin.
Other less important pathways involve the secretion of soluble
cytokines and Fas/FasL interaction.12–15
Degranulation can cause positive expression of CD107a/b on
the cell surface for a brief period of time before these proteins are
internalized again.26 Therefore, expression of CD107 on CD8+ T
cells can be a marker for degranulation. Consequently, expression
of CD107 on the cell surface was reduced in this study in the
presence of LEV paralleling the reduction in perforin release. This
attenuating effect of LEV on perforin release may help explaining
the higher rates of pharyngitis/rhinitis in LEV-treated patients.5
In addition to its immunological effects, perforin plays also a
role in blood–brain-barrier (BBB) permeability. Recently, it was
reported that CD8+ T lymphocytes can lead to BBB dysfunction
through a perforin-dependent process.27 In recent experiments,
Marchi and co-workers found reduced BBB damage in perforin-
deﬁcient pilocarpine-treated epileptic mice.28 Inducing BBB
disruption may establish a link between the systemic immune
system and the brain.29–32 This leads to the hypothesis that
levetiracetam’s attenuating effect on perforin release adds to itsFig. 3. Apoptosis of CD8+ T lymphocytes after 24 h of incubation dependent on low
and high concentrations of LEV and VPA. After 24 h, cells treated with VPA 100 mg/l
showed signiﬁcantly lower apoptosis rate compared to the control group. Data are
presented as median and interquartile range (IQR). LEV = levetiracetam,
VPA = valproate, *p < 0.01.
G. Li et al. / Seizure 22 (2013) 462–466466anticonvulsant potency via reduction of BBB disruption. Further
studies in this ﬁeld are warranted.
The attenuated degranulation of CD8+ T lymphocytes by LEV is
probably caused by binding to SV2A, the presence of which we
could prove in human CD8+ T lymphocytes. These results are
preliminary and because of the limited number of samples future
examination is warranted for this respect. But this detection is in
line with a recently published study where detection of SV2A
mRNA in T lymphocytes of mice could be documented.33
SV2A was identiﬁed as the binding site of LEV in the brain.3 It
has been reported that SV2A exists in a variety of neurons and
endocrine cells.34–37 In neurons, SV2A is associated with synaptic
vesicle fusion, exocytosis and neurotransmitter release.38 Further
studies are required to verify that SV2A inhibition explains the
depressive effects of LEV on degranulation of human CD8+ T
lymphocytes.
This study did not reveal any effects of VPA on degranulation of
CD8+ T lymphocytes but could show that 100 mg/L of VPA reduced
spontaneous apoptosis of CD8+ T lymphocytes in healthy
volunteers. Similarly, it was reported that healthy donor T cells
were signiﬁcantly less sensitive to induction of apoptosis in the
presence of VPA than primary chronic lymphocytic leukemia
cells.19 This insensitivity was more prominent for high concentra-
tions of VPA than low concentrations. Valproate was found to
induce apoptosis of various leukemia cells in vivo and in vitro
contrasting its effects on healthy T cells.17–19 Therefore, our results
support the view that VPA has antiapoptotic effects.
In conclusion, we could show that LEV had a moderate
depressive effect on degranulation of CD8+ T lymphocytes,
indicating that LEV can disturb the antiviral function of the
immune system. This effect is possibly mediated by SV2A
inhibition and may help to explain the increased incidence of
upper respiratory tract infections in LEV-treated patients.
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